UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 14, 2025 (March 13, 2025)
Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)
|
Cayman Islands
|
|
001-42253
|
|
N/A |
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(I.R.S. Employer
|
|
of incorporation)
|
|
|
|
Identification No.)
|
|
12 Abba Hillel Road Ramat-Gan, Israel |
|
5250606
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered |
|
Ordinary Shares, par value $0.0009 per share
|
|
SLXN |
|
The Nasdaq Stock Market LLC
|
|
Warrants exercisable for Ordinary Shares at an exercise price of $103.50 per share
|
|
SLXNW
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
|
|
|
|
|
||
|
|
|
|
|
104
|
|
Cover Page Interactive Data File (formatted in Inline XBRL)
|
|
|
SILEXION THERAPEUTICS CORP
|
|
|
|
|
|
|
Date: March 14, 2025
|
/s/ Ilan Hadar
|
|
|
|
Name:
|
Ilan Hadar
|
|
|
Title:
|
Chief Executive Officer
|
|
Re:
|
Inducement to Convert Silexion Convertible Promissory Note
|
|
|
(i) |
The Holder hereby notifies the Company that Holder is converting a portion of the Note Balance into the Note Shares at a price per Note Share equal to the Conversion
Price (as amended in paragraph (ii) below). Within one business day after the date hereof, the Company’s transfer agent will deliver the Note Shares to the Holder, free and clear of any restrictive legends, in accordance with the issuance
instructions that appear in Appendix A to this letter agreement.
|
|
|
(ii) |
The contemplated timing for conversion under Section 3 of the Note, and the definition of Conversion Price (as defined in Section 3 of the Note), are hereby amended
such that the Holder may convert as of the date hereof, into the Note Shares, such portion of the Note Balance as is equal to the Conversion Price (as amended below) multiplied by 277,777 (i.e., the number of Note Shares to be issued upon
such conversion). As amended hereby, the term “Conversion Price” in Section 3 of the Note means the average net proceeds per Note Share to be received
by the Holder from the sale of all of the Note Shares in accordance with paragraph (iv) below, after deducting any reasonable and documented selling and other offering expenses incurred by the Holder in connection with the Holder’s sales of
the Note Shares (but without deducting the Collection Fee (as defined in paragraph (iii) below)), as reflected in a written report or certification by the Holder to be provided by Holder to the Company (or other evidence that is reasonably
acceptable to the Company) (the “Note Shares Sales Report”) that states (a) the total proceeds from the sale of all Note Shares, (b) the foregoing
reasonable and documented selling and other offering expenses incurred by the Holder, (c) the resulting aggregate net proceeds from the sale of the Note Shares (the “Aggregate
Net Proceeds”), and (d) the calculation of the Conversion Price (which shall equal the Aggregate Net Proceeds, divided by 277,777).
|
|
|
(iii) |
Concurrently with the execution of this letter agreement, the Company shall make a cash payment by wire transfer to the Holder, to the account t designated by the
Holder as set forth on Appendix B hereto (the “Directed Account”), in an amount of $415,000, consisting of (x) $400,000 (the “Pre-Payment
Amount”) to be applied to payment of, and to be deducted from, the Note Balance, and (y) $15,000 for the collection/legal fees of the Holder (the “Collection
Fee”).
|
|
|
(iv) |
Holder agrees that all sales of the Note Shares shall be carried out in broker transactions, on the Nasdaq Stock Market, and in keeping with (and not below) market
prices as of the time of such sales. The Holder represents and warrants that any sales of Note Shares shall be conducted in accordance with the Plan of Distribution as set forth in the Registration Statement, and that the Holder will comply
with any prospectus delivery requirements of the Securities Act of 1933, as amended.
|
|
|
(v) |
Upon Holder’s notification to the Company that the sale of all Note Shares has been completed, and after providing the Note Shares Sales Report to the Company, and the
Company’s acknowledgment that such report is in good order (which acknowledgement shall not be unreasonably withheld or delayed), the Company shall promptly (no later than the first (1st) trading day afterwards) make a cash payment by wire
transfer to the Holder, to the Directed Account, in an amount (the “Settlement Amount”) equal to the difference between (i) the Note Balance, less (ii) the sum of (a) the Aggregate Net Proceeds and (b) the Pre-Payment Amount. To the extent the Settlement Amount is a negative number,
Holder shall promptly (no later than the first (1st) trading day after Holder’s delivery of the Note Shares Sales Report to the Company) make a cash payment by wire transfer to the Company in the amount by which the sum of the Aggregate Net
Proceeds and the Pre-Payment Amount exceed the Note Balance (such amount, the “Excess Repayment Amount”).
|
|
|
(vi) |
Upon acknowledgement of receipt by the Holder of the Settlement Amount, or, in the case the Settlement Amount is a negative number, upon confirmation by the parties
that the Holder is required to repay the Excess Repayment Amount, the Note shall be automatically considered repaid and retired, with no further obligations of the Company thereunder (but subject to the Holder’s obligation to refund the
Excess Repayment Amount to the Company, to the extent applicable). At such time, the Holder shall promptly return the original signed Note to the Company, or shall deliver an acknowledgment as to the repayment of, and retirement of, the Note
to the Company. If the Company is obligated to pay a Settlement Amount to the Holder and such payment is not made as set forth herein (a “Payment Default”), then the Note shall remain outstanding and in full force and effect, including
provisions related to penalty interest, with (i) the amount owed thereunder deemed to be the Settlement Amount and (ii) interest accruing on such amount from the date of the Payment Default at the penalty interest rate as set forth in the
Note.
|
|
|
Sincerely yours,
|
|
|
|
|
|
|
|
SILEXION THERAPEUTICS CORP
|
|
|
|
|
|
|
|
By:
|
/s/ Ilan Hadar
|
|
|
Name:
|
Ilan Hadar
|
|
|
Title:
|
Chief Executive Officer
|
|
|
By:
|
/s/ Mirit Horenshtein Hadar
|
|
|
Name:
|
Mirit Horenshtein Hadar
|
|
|
Title:
|
Chief Financial Officer
|